SANOFI US SERVICES INC. for SANOFI US SERVICES INC
What was lobbied
8 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Provision: Division B-Zika response and preparedness under bill H.R. 3525 "Legislative Branch Appropriations Act, 2017".
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY L REDL | — |
Trade (domestic/foreign) TRD
Issues related to Trans Pacific Partnership.
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JACOB ANDREW HARTSFIELD | — |
Medicare/Medicaid MMM
Provisions of S31 "Medicare Prescription Drug Price Negotiation Act.
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARYANNE DOLBEARE DUNLAP | — |
Taxation/Internal Revenue Code TAX
All provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"; issues related to Department of Treasury regulations on inversions.
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARYANNE DOLBEARE DUNLAP | — |
| AMY L REDL | — |
Copyright/Patent/Trademark CPT
General issues related to international intellectual property.
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JACOB ANDREW HARTSFIELD New | — |
Health Issues HCR
Issues related to the Over The Counter (OTC) Monograph reform; general issues related to Zika Outbreaks;general issues related to the value of prescription medicines; issues related to S. 3900 Amendment for Zika Response and Preparedness; issues related to H.R. 5243 "Zika Response Appropriations Act, 2016"; education and awareness of Dengue; issues related to the Independent Payment Advisory Board IPAB; issues related to Center for Medicaid and Medicaid Services Innovation Center; all issues related to the Innovation for Healthier Americans Initiative; Issues related to research and development innovation and education; general issues related to emerging infectious diseases; general issues related to counterfeit pharmaceuticals; issues related to H.R. 3678 "Preserving Access to Orphan Drug Act of 2015"; general issues related to importation; general issues related to insulin pricing; general issues related to priority review vouchers; and general issues related to Tropical Disease PRV Program.
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARYANNE DOLBEARE DUNLAP | — |
| AMY L REDL | — |
| FRANCIS JOGUES RIENZO | — |
Animals ANI
Issues related to animal compounding.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARYANNE DOLBEARE DUNLAP | — |
Pharmacy PHA
General issues related to the 340B Federal Drug Pricing Program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARYANNE DOLBEARE DUNLAP | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.